Showing 4921-4930 of 5771 results for "".
- Vision Health Initiative Named a Mutual of America 2019 Community Partnership Award Winnerhttps://modernod.com/news/vision-health-initiative-named-a-mutual-of-america-2019-community-partnership-award-winner/2477094/Mutual of America announced that “Seeing the Future: Vision Health Initiative” was named a Merit Finalist award recipient of its 2019 Community Partnership Award competition. Seeing the Future: Vision Health Initiative was launched by Care For the Homeless (CFH) in 2016 after r
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea
- Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technologyhttps://modernod.com/news/armenian-eyecare-project-surpasses-milestone-of-10000-patients-screened-using-artificial-intelligence-eye-screening-technology/2477088/On this World Diabetes Day, the Armenian EyeCare Project (AECP), a nonprofit organization dedicated to eliminating preventable blindness in Armenia, announced that it has surpassed the milestone of screening 10,000 patients for diabetic retinopathy (DR) throughout Armenia utilizing the state-of-a
- ELT Sight Acquires Assets and IP of MLase AG Excimer Ophthalmic Laser System for Glaucoma Surgeryhttps://modernod.com/news/elt-sight-acquires-assets-and-ip-of-mlase-ag-excimer-ophthalmic-laser-system-for-glaucoma-surgery/2477086/ELT Sight announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. Terms for the acquisition were not disclosed. MLase manufactures and markets laser systems, including the ExTra ELT Laser and disposable applicator used
- Eversight Awarded $50,000 to Investigate Cell Expansion to Address Global Cornea Shortagehttps://modernod.com/news/eversight-awarded-50000-to-investigate-cell-expansion-to-address-global-cornea-shortage/2477085/Eversight announced the Eye Bank Association of America (EBAA) awarded a $50,000 High Impact Research Grant to the organization and its research partners to investigate cell expansion aiming to mitigate the global shortage of surgical quality donor corneas available for transplantation. Mo
- Eyecloud Moist Heat Therapy Now Directly Available to Dry Eye Patientshttps://modernod.com/news/eyecloud-moist-heat-therapy-now-directly-available-to-dry-eye-patients/2477084/Eye Eco announced the direct-to-patient launch of eyecloud, a moist heat therapy system that provides dry eye patients sustained, relaxing relief. The eyecloud system, which uses patented, professional-grade technology to evenly warm and hydrate the eyelids and surrounding skin, has been used by
- EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/ema-and-fda-accept-marketing-applications-for-chugais-satralizumab-in-neuromyelitis-optica-spectrum-disorder-nmosd/2477062/Chugai Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab, an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum
- Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Diseasehttps://modernod.com/news/integrated-clinical-trial-analyses-further-substantiate-that-teprotumumab-significantly-improves-debilitating-effects-of-thyroid-eye-disease/2477063/Horizon Therapeutics announced integrated, pooled efficacy data from the phase 2 and phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulg
- Johnson & Johnson Vision Launches Tecnis Eyhance Monofocal IOL in Indiahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-eyhance-monofocal-iol-in-india/2477059/Johnson & Johnson Vision announced the launch of Tecnis Eyhance IOL, which is designed to extend depth of focus from distance to intermediate vision. Over the past several decades, India’s eye care system has made tremendous strides towards high q
- EyePrint Prosthetics Releases New Scleral Lens Technology: ScanFitPROhttps://modernod.com/news/eyeprint-prosthetics-releases-new-scleral-lens-technology-scanfitpro/2477058/EyePrint Prosthetics has announced the development of its new scleral lens fitting software, ScanFitPRO. This new technology simplifies every-day contact lens fitting by employing EyePrint Prosthetic’s scleral lens designer algorithm to automatically design a lens in 3-dimensional space, accordin